纤维连接蛋白诱导CIK细胞治疗晚期癌症患者的安全性及疗效评价  

Therapeutic Safety and Effects of Cytokine Induced Killer Cells Activated by RetroNectin for Advanced Cancer Patients

作　　者：王士勇[1] 张晖[1] 杜微丽[1] 张远[1] 乌兰图雅[1] 何英[1] 刘飒[1] 张哲[1] 王佳玲[1] 武秀艳[1] 

机构地区：[1]中国医科大学附属第四医院生物治疗科,沈阳市110032

出　　处：《中国肿瘤临床》2009年第20期1163-1166,共4页Chinese Journal of Clinical Oncology

基　　金：教育部留学回国人员科研启动基金资助(编号:2004-527)~~

摘　　要：目的:评价重组人纤维连接蛋白(Retro Nectin,RN)诱导的CIK细胞治疗晚期癌症患者的安全性及疗效。方法:观察85例晚期癌症患者,经RN诱导的自体或异体血CIK细胞治疗的安全性。选择晚期非小细胞肺癌患者36例,分为2组:CIK细胞治疗组20例,化疗组16例,比较两组治疗前后的免疫功能、生活质量(用汉化生活量表QLICP系统测试)、临床疗效差异;选择晚期非小细胞肺癌患者32倒,分为CIK细胞治疗组及姑息治疗组各16例,比较两组患者的生存期。结果:安全性:自体及异体CIK细胞治疗过程中主要出现兴奋感、失眠、低热,未见明显毒副反应。近期疗效:20例患者经CIK细胞治疗:PR 1例,SD 10例,PD 9例,ORR 5.00%,DCR 55.00%;16例患者经化疗:PR 5例,SD 5例,PD 6例,ORR 31.25%,DCR 62.50%,2组的DCR差异不显著(P>0.05),但化疗组的ORR明显高于CIK组(P<0.05)。在生活质量方面,化疗后病人心理模块中情绪方面明显低落(P<0.05),CIK细胞治疗的患者多有生活质量提高;CIK细胞治疗组与化疗组患者,治疗前后免疫功能无显著差异(P>0.05)。CIK细胞治疗组(11.0个月)比姑息治疗组(6.0个月)中位生存期延长,但总生存时间无统计差异(x^2=2.301,P=0.129)。结论:RN诱导的CIK细胞自体及异体治疗均简便、安全、有效,可以改善晚期肿瘤病人的生活质量,延长生存期。Objective： To evaluate the safety and therapeutic effects of Cytokine Induced Killer （CIK） cells activated by RetroNectin for patients with advanced malignant tumor. Methods： We observed 85 patients with advanced malignant tumor who received blood from CIK from autologous or homologous between December 2007 and March 2009 to evaluate the therapeutic safety of CIK cells activated by RetroNectin. We selected 36 cases of non-small cell lung cancer （NSCLC） patients and divided them into CIK therapy group （20 cases） and chemotherapy group （16 cases）. Patients＇ immunologic function, life quality （according to Chinese Edition Software Living Measurement Sheet-QLICP）, and therapeutic effects at two weeks after treatment with CIK and chemotherapy were compared between the two groups. We also chose 32 cases of NSCLC and divided into chemotherapy group （16 cases） and palliative treatment group （16 cases）. The patient survival was compared between the two groups. Results： No severe side effects were found during or after CIK cell transfusion except euphoria, insomnia and fever. In the 20 cases of NSCLC patients treated with CIK, there was 1 PR case, 10 SD cases and 9 PD cases; the ORR was 5% and the DCR was 55%. In the 16 NSCLC patients treated with chemotherapy, there were 5 PR cases, 5 SD cases and 6 PD cases; the ORR was 31.25% and DCR was 62.50%. No significant difference was found in DCR between the two groups （P〉0.05）. ORR of the chemotherapy group was higher than that in the CIK group （P〈0.05）. Patients in the chemotherapy group were obviously depressed （P〈0.05）. Patients in the CIK group had improvement in apetite, and physical and mental activity. No significant difference was found in cellular and humoral immunity between the two groups （P〉0.05）. The median survival of the CIK group （11.0 months） was longer than that of the palliative treatment group （6.0 months）, But no statistical significance was found in the overall survival between the two gro

关 键 词：CIK细胞 过继免疫治疗 恶性肿瘤 生命质量 

分 类 号：R730.5[医药卫生—肿瘤]